Active Pharmaceutical Ingredients

PRODUCTS

API’s Category Specifications Regulatory Status
Atenolol Anti-Hypertensive IP/BP/EP/USP CEP available, EU GMP, USDMF, CADIFA Filed
Amlodipine Besylate Anti-Hypertensive IP/BP/EP/USP DMF available, CADIFA Filed, CEP available
Metoprolol Succinate Anti-Hypertensive IP/BP/EP/USP USDMF filed, CADIFA filed
Metoprolol Tartrate Anti-Hypertensive IP/BP/EP/USP USDMF filed
Roxithromycin Macrolides IP/BP/EP CEP available
Azithromycin Macrolides IP/BP/EP/USP CEP available, USDMF filed, CADIFA Filed
Clarithromycin Granules 27.5% Macrolides In-House DMF Available
Clarithromycin Granules 33% / 30% Macrolides In-House DMF Available
Clarithromycin Granules 43% / 42% Macrolides In-House DMF Available
Pregabalin Neuromodulator IP/EP/BP/USP CEP available, USDMF filed, CADIFA Filed, KDMF filed
Meropenem (with Sodium Carbonate) for Injection Carbapenems IP/USP DMF available
Doripenem Carbapenems JP/In-House DMF available
Biapenem Carbapenems In-House DMF available
Ertapenem Carbapenems In-House DMF under compilation
Faropenem Carbapenems JP/In-House DMF available
Tebipenem Carbapenems In-House DMF available
Imipenem Carbapenems In-House Non Sterile Grade / Sample available
Lymecycline Anti-Acne, Anti-Infective EP DMF available, CEP available
Nitroxoline Antibiotic (Urological) In-House ASMF available, USDMF under compilation
Ticagrelor Anti-Thrombotic IP/EP/In-House DMF available, CEP application under compilation
Rivaroxaban Anti-Thrombotic EP/USP/In-House CEP application filed
Apixaban Anti-Thrombotic In-House DMF available
Edoxaban Tosylate Anti-Thrombotic In-House DMF available
Empagliflozin Anti-Diabetic In-House DMF available
Dapagliflozin Propanediol Monohydrate Anti-Diabetic In-House DMF available, CEP application filed
Montelukast Sodium Anti-Asthamatic IP/EP/USP DMF under compilation
Rosuvastatin Calcium Antihyperlipidemic IP/EP/USP DMF under compilation
Lacosamide Anti-convulsants EP/USP DMF under compilation
Buspirone Hydrochloride Anti-Anxiety IP/EP/USP DMF under compilation
Riociguat Pulmonary Arterial Hypertension EP/USP DMF under compilation
Macitentan Pulmonary Arterial Hypertension In-House DMF under compilation
Vericiguat Chronic heart failure In-House DMF under compilation
Mirogabalin Neuropathic Pain In-House DMF under compilation
Vonoprazan Fumarate Erosive esophagitis In-House DMF under compilation

PELLETS

Pellets Category
Duloxetine Pellets 17%, 21.5% Anti-Depressant
Venlafaxine Pellets 33% Anti-Depressant
Dexlansoprazole Pellets 20%, 23% Proton Pump Inhibitor

PRODUCTS UNDER DEVELOPMENT

API’s Category Sample Availability Tech Pack Availability
Canagliflozin Hemihydrate Anti-Diabetic Available Available
Ertugliflozin L-pyroglutamic acid Anti-Diabetic Available Available
Ivacaftor Cystic fibrosis Available Available
Briveracetam Anti-epileptic, Neuromodulator Nov-25 Dec-25
Finerenone Cardiovascular, Nephrology Nov-25 Dec-25
Rimegepant Anti-migraine Feb-26 Mar-26
Atogepant Anti-migraine Feb-26 Mar-26
Bempedoic Acid Antihyperlipidemic Dec-25 Jan-26
Vibegron Treatment of overactive bladder Mar-26 Apr-26
Upadacitinib Rheumatoid Arthritis Mar-26 Apr-26
Sulopenem Etzadroxil Carbapenems Apr-26 May-26
Avatrombopag Platelet enhancing drug Mar-26 Apr-26

NOTE

  • Products will not be offered for sale in countries where valid Patents are in force.
  • It is the responsibility of the buyer to comply with the above.

For more information on API’s, send an e-mail to: api@kopran.com